Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF



GREY:IPHAF - Post by User

Comment by labumbaon Apr 24, 2010 2:53pm
551 Views
Post# 17027759

RE: MAJOR, MAJOR KICK IN THE GROIN!

RE: MAJOR, MAJOR KICK IN THE GROIN!Major, major kick in the groin ?......not quite.....Zortress is not the first line of defense in terms of immunosuppression...it still needs to combine with Cyclosporin in a drug therapy to treat patients after the critical acute organ rejection period.......it is an enhance drug for a long term treatment for kidney transplanted patients


--------------------------------------------------

 "  The US Food and Drug Administration (FDA) has approved Zortress (everolimus) oral tablets for the prevention of organ rejection of kidney transplants in adult patients at low-to-moderate immunologic risk. Zortress is to be given in combination with reduced doses of the calcineurin inhibitor (CNI) cyclosporine, as well as basiliximab and corticosteroids[4].
<< Previous
Bullboard Posts
Next >>